French pharmaceutical giant Sanofi has seen its US$8.5 billion portfolio of older, off-patent drugs draw interest from private-equity firms KKR, Blackstone Group and TPG Capital, Bloomberg reported, citing people with knowledge of the matter.
Sanofi is said to be reviewing options for its mature-drug portfolio. According to an internal Sanofi document circulated by a labor union this month, the portfolio has an enterprise value of 6.3 billion euro (US$8.5 billion), the report said.
Sanofi has held talks with Mylan, Abbott Laboratories and firms such as Warburg Pincus about a possible sale of its mature-products portfolio in Europe, and has also been considering possible partnerships for the assets, the document showed.
While Sanofi CEO Chris Viehbacher is keen to find a solution for the portfolio, carving out the drugs is complicated and may make a transaction difficult, sources were quoted as saying.
Sanofi doesn’t yet have financial information for the private-equity firms to examine for due diligence, according to the report.
– Contact us at [email protected]